Envoy Medical, Inc. 8-K

What Happened
Envoy Medical, Inc. (COCH) filed an 8-K (dated June 25, 2026) disclosing that its Compensation Committee on June 19, 2026 approved changes to CEO Brent Lucas’s compensation. Mr. Lucas’s new base salary is $420,000 per year and he is eligible for a cash bonus targeted at $105,000 based on strategic goals for 2026–2027. The company also granted him 1,000,000 stock options and 1,000,000 restricted stock units (RSUs).

Key Details

• Base salary: $420,000 per year (approved June 19, 2026).
• Bonus: cash bonus targeted at $105,000 tied to achievement of strategic performance goals during calendar years 2026–2027.
• Equity grants: 1,000,000 stock options (exercise price $0.634 — the most recent closing price prior to grant) and 1,000,000 RSUs. Options vest over four years and follow the company’s standard terms.
• RSU vesting: RSUs vest upon official FDA notification of approval (including conditional approval) for Envoy’s Acclaim cochlear implant, provided that such FDA announcement occurs during the performance period from June 19, 2026 through June 18, 2030.

Why It Matters
This filing shows the company tying executive pay to both near-term strategic goals (cash bonus) and a major regulatory milestone (FDA approval of the Acclaim cochlear implant). For investors, the grants align the CEO’s incentives with product approval and long-term performance but also represent potential future dilution if options are exercised and RSUs settle in shares. Monitor progress on the FDA approval and any future filings that quantify potential dilution or additional details on equity plan impacts.